Coherus CSV revenue up 15% as pipeline studies advance
Coherus reports LOQTORZI revenue of $13.6 million for Q2 2026. Clinical data continues to mature across programs, with preliminary evidence of activity featuring a new cancer asset.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day